05/02/2025 / By Lance D Johnson
The U.S. government is doubling down on failed vaccine science, pouring half a billion taxpayer dollars into a futile quest for “universal” vaccines against influenza and coronaviruses. The Department of Health and Human Services (HHS) and National Institutes of Health (NIH) announced the “Generation Gold Standard” initiative, a repackaged version of Biden’s failed Project NextGen, which itself was a continuation of the disastrous Operation Warp Speed.
Despite decades of evidence showing that respiratory viruses mutate too quickly for vaccines to keep up, bureaucrats and captured scientists are pushing forward with beta-propiolactone (BPL)-inactivated whole-virus vaccines—a 70-year-old technology that has never delivered on the promise of universal protection.
Key Points:
The NIH’s Dr. Jay Bhattacharya called the program a “paradigm shift,” but independent scientists aren’t buying it. Dr. Meryl Nass, a longtime vaccine safety advocate, told The Defender: “This holy grail in vaccinology has been sought for decades, so far unsuccessfully. The press release fails to tell us how this method is suddenly going to produce the holy grail.”
BPL technology, while safer than mRNA, still carries risks. Epidemiologist Nicolas Hulscher of the McCullough Foundation cautioned: “Any injectable product delivering toxic antigens—even if inactivated—can still result in serious adverse events, especially if distributed at scale without rigorous long-term, double-blind, placebo-controlled trials.”
HHS claims all new vaccines will now undergo placebo-controlled testing—a tacit admission that previous COVID-19 vaccines were rushed without proper safety checks. But will this be enforced, or is it just another empty promise?
The beta-propiolactone (BPL)-inactivated, whole-virus platform is a vaccine production method that uses chemically inactivated whole viruses to induce an immune response. Here’s how it works and why it’s significant:
Whole-virus approach
Inactivation with beta-propiolactone (BPL)
Safety & efficacy
Examples of use
While HHS boasts that this is a “government-owned” project, the reality is that Big Pharma will still profit. The NIH has long been a revolving door for pharmaceutical executives, and the “public-private partnership” model ensures that taxpayer money ultimately flows to corporate interests.
Children’s Health Defense (CHD) CEO Mary Holland noted the irony: “It’s interesting that this doesn’t direct payments to Big Pharma, but the question is: Will the NIH resist industry pressure when these vaccines inevitably fail?”
The timeline is equally suspect:
By then, the viruses will have mutated beyond recognition, rendering any “universal” vaccine obsolete.
The fundamental flaw in this approach is the ignorance of mucosal immunity—the body’s first line of defense in the respiratory tract. Vaccines injected into muscle tissue cannot replicate the full-spectrum immune response generated by natural infection.
Moreover, individual microbiomes play a critical role in immune function—a factor completely ignored by one-size-fits-all vaccine programs. Instead of wasting billions on doomed vaccine projects, why not invest in:
The U.S. government is repeating the same mistakes that led to the COVID-19 vaccine disaster—pumping money into a broken system while ignoring the science of natural immunity. Infectious diseases will never be eradicated, but the population can become healthier, with a broader approach to immune system health that evolves herd immunity of the population through healthy infection recovery and natural immunity.
Sources include:
Tagged Under:
. vaccines, Big Pharma, BPL technology, coronavirus, corruption, Generation Gold Standard, government waste, HHS, immune system, influenza, medical fraud, medical freedom, MERS-CoV, microbiome, natural immunity, NIH, Operation Warp Speed, placebo trials, Project NextGen, Public Health, respiratory viruses, SARS-CoV-2, universal vaccines, vaccine failure, Vaccine injuries
This article may contain statements that reflect the opinion of the author